NTLA Intellia Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NTLA

Price (delayed)

$20.02

Market cap

$1.92B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.42

Enterprise value

$1.81B

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and Virginijus Šikšnys . The company has partnerships with Novartis and Regeneron. ...

Highlights
The EPS has grown by 12% YoY
The company's debt fell by 12% YoY and by 2.5% QoQ
The gross profit has contracted by 30% YoY and by 30% from the previous quarter
Intellia Therapeutics's revenue has decreased by 30% YoY and by 30% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.intelliatx.com/
Peers: OMER OMGA

Key stats

What are the main financial stats of NTLA
Market
Shares outstanding
96.11M
Market cap
$1.92B
Enterprise value
$1.81B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.71
Price to sales (P/S)
48.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.97
Earnings
Revenue
$36.28M
EBIT
-$481.19M
EBITDA
-$472.22M
Free cash flow
-$408.07M
Per share
EPS
-$5.42
Free cash flow per share
-$4.6
Book value per share
$11.73
Revenue per share
$0.41
TBVPS
$14.66
Balance sheet
Total assets
$1.3B
Total liabilities
$250.81M
Debt
$115.35M
Equity
$1.05B
Working capital
$883.12M
Liquidity
Debt to equity
0.11
Current ratio
8.67
Quick ratio
8.23
Net debt/EBITDA
0.24
Margins
EBITDA margin
-1,301.8%
Gross margin
100%
Net margin
-1,326.5%
Operating margin
-1,420.5%
Efficiency
Return on assets
-36.4%
Return on equity
-43.9%
Return on invested capital
-42.8%
Return on capital employed
-40.6%
Return on sales
-1,326.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NTLA stock price

How has the Intellia Therapeutics stock price performed over time
Intraday
-5.43%
1 week
-6.1%
1 month
-25.38%
1 year
-44.8%
YTD
-34.34%
QTD
-27.23%

Financial performance

How have Intellia Therapeutics's revenue and profit performed over time
Revenue
$36.28M
Gross profit
$36.28M
Operating income
-$515.29M
Net income
-$481.19M
Gross margin
100%
Net margin
-1,326.5%
Intellia Therapeutics's operating margin has shrunk by 62% YoY and by 51% QoQ
The company's net margin fell by 48% QoQ and by 46% YoY
The gross profit has contracted by 30% YoY and by 30% from the previous quarter
Intellia Therapeutics's revenue has decreased by 30% YoY and by 30% QoQ

Growth

What is Intellia Therapeutics's growth rate over time

Valuation

What is Intellia Therapeutics stock price valuation
P/E
N/A
P/B
1.71
P/S
48.99
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
49.97
The EPS has grown by 12% YoY
The stock's P/B is 68% below its 5-year quarterly average of 5.3 and 39% below its last 4 quarters average of 2.8
Intellia Therapeutics's equity has decreased by 15% YoY
The price to sales (P/S) is 47% lower than the 5-year quarterly average of 93.3 and 24% lower than the last 4 quarters average of 64.4
Intellia Therapeutics's revenue has decreased by 30% YoY and by 30% QoQ

Efficiency

How efficient is Intellia Therapeutics business performance
The ROS has contracted by 48% from the previous quarter and by 46% YoY
Intellia Therapeutics's ROIC has increased by 14% YoY but it has decreased by 2.4% from the previous quarter
Intellia Therapeutics's ROE has increased by 10% YoY but it has decreased by 8% from the previous quarter
The ROA has contracted by 8% from the previous quarter but it has grown by 6% YoY

Dividends

What is NTLA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NTLA.

Financial health

How did Intellia Therapeutics financials performed over time
Intellia Therapeutics's total liabilities has increased by 22% QoQ but it has decreased by 12% YoY
The total assets has contracted by 14% YoY but it has grown by 4.6% from the previous quarter
The company's debt is 89% lower than its equity
Intellia Therapeutics's equity has decreased by 15% YoY
The company's debt fell by 12% YoY and by 2.5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.